Eye on Pharma: Celltrion Aims for Adalimumab Interchangeability; Phase ...
Celltrion seeks FDA approval for its adalimumab biosimilar Yuflyma's interchangeability with Humira, aiming for a 2023 launch. Formycon reports positive phase 3 trial results for its ustekinumab biosimilar FYB202, comparable to Stelara in treating psoriasis, highlighting progress in biosimilar development.
Reference News
Eye on Pharma: Celltrion Aims for Adalimumab Interchangeability; Phase ...
Celltrion seeks FDA approval for its adalimumab biosimilar Yuflyma's interchangeability with Humira, aiming for a 2023 launch. Formycon reports positive phase 3 trial results for its ustekinumab biosimilar FYB202, comparable to Stelara in treating psoriasis, highlighting progress in biosimilar development.